HIPRA launched Mhyosphere® PCV ID in Korea, marking a significant milestone in the control of Porcine Circovirus type 2 and Mycoplasma hyopneumoniae. This innovative vaccine is the first ready-to-use intradermal vaccine on the market, setting a new standard for efficiency and convenience in swine health management.

To celebrate this groundbreaking launch, HIPRA Korea organized from December 2nd to 5th, five exclusive events across Korea( Daejeon, Daegu, Jeonju, Gwangju, and Icheon). These presentations brought together over 100 key players in the Korean swine industry, including veterinarians, producers and distributors, all eager to learn about the latest advancements in swine health.

The introduction of Mhyosphere® PCV ID has been met with great anticipation by the veterinary and swine production communities. Its unique formulation and administration method promise enhanced efficacy and ease of use, addressing key challenges in the field.

As part of its commitment to innovation, HIPRA has also unveiled the Hipradermic® UX, a cutting-edge needle-free intradermal vaccination device. This new device complements Mhyosphere® PCV ID, ensuring precise and stress-free vaccine administration for both animals and operators.

HIPRA continues to lead the way in veterinary innovation in Korea, offering solutions that improve animal welfare and optimize productivity, as well as it reaffirms its commitment with the Korean swine industry.